Michael A. Farber

TL;DR: In hypertensive patients with reduced GFR, neither amlodipine nor lisinopril was superior to chlorthalidone in reducing the rate of development of ESRD or a 50% or greater decrement in GFR.

TL;DR: It was found that coronary heart disease was much more common than end-stage renal disease in hypertensive patients with moderate to severe reductions in GFR who were followed for 6 years, and lower baseline GFR was associated with higher risk for CHD independent of other risk factors.

TL;DR: In ALLHAT, with adjudicated outcomes, chlorthalidone significantly reduced the occurrence of new-onset hospitalized HFPEF and HFREF compared with amlodipine and doxazosin and among high-risk hypertensive men and women, HFP EF has a better prognosis than HFREF.

TL;DR: This analysis shows that the slightly worse blood pressure control achieved with doxazosin did not explain higher risks for heart failure, and a low probability existed that doxAZosin would show benefit over chlorthalidone for the primary end point by the scheduled study end, given the lack of difference.

TL;DR: In hypertensive patients with reduced GFR, neither amlodipine nor lisinopril was superior to chlorthalidone in reducing the rate of development of ESRD or a 50% or greater decrement in GFR.